China HeadAche DIsorders RegiStry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorBeijing Tiantan Hospital

About this trial

It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS), patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.

Eligibility criteria

Qualifiers

Age ≥ 12 years old,Any gender;

The first onset age of primary headache was less than 50 years old(Age <65 years at first diagnosis of chronic migraine);

patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3;

Sign the informed consent form.

Disqualifiers

According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment;

Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3;

According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.);

Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year;

Trial design

Treatments tested in this trial

  • Medicine Overuse Headache/New Daily Persistent Headache
  • Episodic Migraine and Chronic Migraine
  • Patients with other types of primary headache
  • Yangxue Qingnao Granules (Pills)
  • Erenumab
  • Eptinezumab

Treatment groups

10,000 Participants
are divided into 4 treatment groups

Sponsors and collaborators